Related Articles
Targeted chemotherapy for triple-negative breast cancers via LHRH receptor
Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line.
Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers
Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.